June 3, 2019, Vancouver, British Columbia: PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), announces that it has received a loan in the aggregate amount of $300,000 (the “Loan”) pursuant to a loan agreement with the Company’s Chairman and Chief Executive Officer, Mr. Stephen Van Deventer (the “Lender”).

The Loan has a one-year term and will bear interest at a rate of 5% per annum, compounded semi-annually and payable on the maturity date.  Pursuant to the Loan, the Company has also granted 5,000,000 transferable bonus common share purchase warrants (each, a “Bonus Warrant”) to the Lender.  Each Bonus Warrant will entitle the holder to purchase one common share in the capital of the Company at an exercise price of $0.06 per share for a period of one year from the grant date.  All securities issued pursuant to the Loan will be subject to a hold period of four months and one day in Canada from the date of issuance.  The funds received by the Company from the Loan will be used for general working capital purposes.

As the Lender is a current director and executive officer of the Company, the Loan constituted a related party transaction pursuant to Multilateral Instrument 61 101 - Protection of Minority Security Holders in Special Transactions (“MI 61-101”).  The Company relied on Sections 5.5(a) and 5.7(1)(a) of MI 61-101 for an exemption from the formal valuation and minority shareholder approval requirements, respectively, of MI 61-101, as, at the time the Loan was made available to the Company, neither the fair market value of the subject matter of, nor the fair market value of the consideration for the Loan exceeded 25% of the Company’s market capitalization.

Mr. Greg Reid has stepped down as a director of the Company, effective May 31, 2019, to allow for more time to focus on his film making career and Keynote Speaker commitments.

PreveCeutical’s President and Chief Science Officer, Dr. Mak Jawadekar stated,

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilising organic and nature identical products.

PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

For more information about PreveCeutical,
please visit www.PreveCeutical.com, follow us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.

On Behalf of the Board of Directors

“Dr. Makarand (Mak) Jawadekar”
President& Chief Science Officer

For further information, please contact:

Deanna Kress
Director of Corporate Communications & Investor Relations
+1-778-999-6063
deanna@PreveCeutical.com